(Q24246323)

English

Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome

scientific article

In more languages

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome (English)

0 references

polycystic ovary syndrome

1 reference

based on heuristic

inferred from title

cardiovascular disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

endometrial cancer

1 reference

based on heuristic

inferred from title

combined oral contraceptive pill

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

polycystic ovary

1 reference

based on heuristic

inferred from title

author name string

Michael F Costello

1

0 references

Bhushan Shrestha

2

0 references

John Eden

3

0 references

Neil Johnson

4

0 references

Lisa J Moran

5

0 references

publication date

24 January 2007

0 references

Cochrane Database of Systematic Reviews

0 references

The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Androgen excess in women: experience with over 1000 consecutive patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Insulin sensitizers for polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Should unpublished data be included in meta-analyses? Current convictions and controversies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Publication bias and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Pharmacologic Treatment of Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

20 µg versus >20 µg estrogen combined oral contraceptives for contraception

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Polycystic ovary syndrome and endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Systematic literature review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Metformin: new understandings, new uses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Insulin resistance: a chicken that has come to roost

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Hormones, genetic factors, and gender differences in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Combined oral contraceptives in the treatment of polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Long-term health consequences of PCOS.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Polycystic ovary syndrome: a risk for coronary artery disease?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

21 January 2018

Endometrial carcinoma; ovarian dysfunction--a risk factor in young women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin and the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005552.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD005552.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24246323&oldid=1953584647"